Evolution of Acute Upper GI Bleeding Management: Lessons from the 2022 UK National Audit

Introduction and Context

Acute upper gastrointestinal bleeding (AUGIB) remains one of the most common and challenging medical emergencies worldwide. Defined by the sudden onset of symptoms such as haematemesis (vomiting blood), melaena (black, tarry stools), or haematochezia (bright red blood per rectum), it accounts for a significant proportion of emergency hospital admissions. For clinicians, AUGIB is a race against time, requiring rapid stabilization, accurate risk assessment, and often, urgent endoscopic intervention.

In the United Kingdom, the landscape of AUGIB management is periodically assessed through large-scale national audits. The most recent iteration, the 2022 UK Audit, comes fifteen years after its predecessor in 2007. Since that time, the medical landscape has shifted dramatically. The population is aging, the prevalence of multi-morbidity is rising, and the widespread use of direct oral anticoagulants (DOACs) has replaced older therapies. This updated audit provides a critical temperature check on how healthcare systems have adapted to these changes and where significant gaps in care still exist. This guideline-based summary explores the core findings of the 2022 audit and the expert consensus on how to further improve patient outcomes.